Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Reactivity of a monoclonal antibody with human ovarian carcinoma.

Literature DB >> 7028788

Reactivity of a monoclonal antibody with human ovarian carcinoma.

R C Bast, M Feeney, H Lazarus, L M Nadler, R B Colvin, R C Knapp.

Abstract

A murine monoclonal antibody (OC125) has been developed that reacts with each of six epithelial ovarian carcinoma cell lines and with cryopreserved tumor tissue from 12 of 20 ovarian cancer patients. By contrast, the antibody does not bind to a variety of nonmalignant tissues, including adult and fetal ovary. OC125 reacts with only 1 of 14 cell lines derived from nonovarian neoplasms and has failed to react with cryostat sections from 12 nonovarian carcinomas.

Entities: CellLine Disease Species

Mesh：

Substances：

Year: 1981 PMID： 7028788 PMCID： PMC370929 DOI： 10.1172/jci110380

Source DB: PubMed Journal: J Clin Invest ISSN： 0021-9738 Impact factor: 14.808

37 in total

1. Bone marrow-derived lymphoid cell lines from patients with agammaglobulinemia.

Authors: J Schwaber; H Lazarus; F S Rosen
Journal: J Clin Invest Date: 1978-08 Impact factor: 14.808

2. Carcinoembryonic antigen in ovarian epithelial cystadenocarcinomas: the prognostic value of tumor and serial plasma determinations.

Authors: J R van Nagell; E S Donaldson; E C Gay; R M Sharkey; P Rayburn; D M Goldenberg
Journal: Cancer Date: 1978-06 Impact factor: 6.860

3. Hybrid plasmacytoma production: fusions with adult spleen cells, monoclonal spleen fragments, neonatal spleen cells and human spleen cells.

Authors: R H Kennett; K A Denis; A S Tung; N R Klinman
Journal: Curr Top Microbiol Immunol Date: 1978 Impact factor: 4.291

4. Analysis of human ovarian tumor antigens using heterologous antisera: detection of new antigenic systems.

Authors: N Imamura; T Takahashi; K O Lloyd; J L Lewis; L J Old
Journal: Int J Cancer Date: 1978-05-15 Impact factor: 7.396

5. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies.

Authors: M Herlyn; Z Steplewski; D Herlyn; H Koprowski
Journal: Proc Natl Acad Sci U S A Date: 1979-03 Impact factor: 11.205

6. Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.

Authors: R C Young; B A Chabner; S P Hubbard; R I Fisher; R A Bender; T Anderson; R M Simon; G P Canellos; V T DeVita
Journal: N Engl J Med Date: 1978-12-07 Impact factor: 91.245

7. Subset derivation of T-cell acute lymphoblastic leukemia in man.

Authors: E L Reinherz; L M Nadler; S E Sallan; S F Schlossman
Journal: J Clin Invest Date: 1979-08 Impact factor: 14.808

8. Intravenous Corynebacterium parvum: an adjunct to chemotherapy for resistant advanced ovarian cancer.

Authors: B Rao; H J Wanebo; M Ochoa; J L Lewis; H F Oettgen
Journal: Cancer Date: 1977-02 Impact factor: 6.860

9. Study of antibodies against human melanoma produced by somatic cell hybrids.

Authors: H Koprowski; Z Steplewski; D Herlyn; M Herlyn
Journal: Proc Natl Acad Sci U S A Date: 1978-07 Impact factor: 11.205

10. Purification of human ovarian tumor-associated antigen and demonstration of circulating tumor antigen in patients with advanced ovarian malignancy.

Authors: S Knauf; G I Urbach
Journal: Am J Obstet Gynecol Date: 1977-04-01 Impact factor: 8.661

336 in total

1. Characterization of four novel epithelial ovarian cancer cell lines.

Authors: D M Provencher; H Lounis; L Champoux; M Tétrault; E N Manderson; J C Wang; P Eydoux; R Savoie; P N Tonin; A M Mes-Masson
Journal: In Vitro Cell Dev Biol Anim Date: 2000-06 Impact factor: 2.416

2. Serum sialyl Lewis X-i antigen in lung adenocarcinoma and idiopathic pulmonary fibrosis.

Authors: H Satoh; H Ishikawa; Y T Yamashita; M Ohtsuka; K Sekizawa
Journal: Thorax Date: 2002-03 Impact factor: 9.139

3. Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16.

Authors: Thapi Dharma Rao; Kay J Park; Peter Smith-Jones; Alexia Iasonos; Irina Linkov; Robert A Soslow; David R Spriggs
Journal: Appl Immunohistochem Mol Morphol Date: 2010-10

4. NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.

Authors: Alan P Venook; Maria E Arcila; Al B Benson; Donald A Berry; David Ross Camidge; Robert W Carlson; Toni K Choueiri; Valerie Guild; Gregory P Kalemkerian; Razelle Kurzrock; Christine M Lovly; Amy E McKee; Robert J Morgan; Anthony J Olszanski; Mary W Redman; Vered Stearns; Joan McClure; Marian L Birkeland
Journal: J Natl Compr Canc Netw Date: 2014-11 Impact factor: 11.908

Review 5. Protein biomarkers of ovarian cancer: the forest and the trees.

Authors: Brian M Nolen; Anna E Lokshin
Journal: Future Oncol Date: 2012-01 Impact factor: 3.404

6. Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer.

Authors: Tugan Bese; Merve Barbaros; Elif Baykara; Onur Guralp; Salih Cengiz; Fuat Demirkiran; Cevdet Sanioglu; Macit Arvas
Journal: J Gynecol Oncol Date: 2010-12-31 Impact factor: 4.401

10. Monoclonal antibodies to antigens associated with transitional cell carcinoma of the human urinary bladder. I. Determination of the selectivity of six antibodies by cell ELISA and immunofluorescence.

Authors: H Koho; S Paulie; H Ben-Aissa; I Jónsdóttir; Y Hansson; M L Lundblad; P Perlmann
Journal: Cancer Immunol Immunother Date: 1984 Impact factor: 6.968